Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma
BACKGROUND Vascular endothelial growth factor C (VEGF‐C) plays an important role in lymphangiogenesis and activates VEGF receptor 3 (VEGFR‐3). By contrast, lymphatic spread is an important prognostic factor in patients with nonsmall cell lung carcinoma (NSCLC). The objective of the current study was...
Gespeichert in:
| Veröffentlicht in: | Cancer 2003-01, Vol.97 (2), p.457-464 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 464 |
|---|---|
| container_issue | 2 |
| container_start_page | 457 |
| container_title | Cancer |
| container_volume | 97 |
| creator | Arinaga, Mitsuyuki Noguchi, Tsuyoshi Takeno, Shinsuke Chujo, Masao Miura, Takashi Uchida, Yuzo |
| description | BACKGROUND
Vascular endothelial growth factor C (VEGF‐C) plays an important role in lymphangiogenesis and activates VEGF receptor 3 (VEGFR‐3). By contrast, lymphatic spread is an important prognostic factor in patients with nonsmall cell lung carcinoma (NSCLC). The objective of the current study was to determine whether the expression of VEGF‐C and VEGFR‐3 correlates with clinicopathologic factors and prognosis in patients with primary NSCLC.
METHODS
The authors conducted a retrospective review of 180 consecutive patients who underwent complete resection for NSCLC and who did not receive any chemotherapy or radiotherapy prior to surgery. Immunohistochemical staining for VEGF‐C and VEGFR‐3 was performed. The clinicopathologic implications of VEGF‐C and VEGFR‐3 expression were analyzed statistically.
RESULTS
Of 180 patients with NSCLC, 137 patients (76.1%) were positive for VEGF‐C, and 40 patients (22.2%) were positive for VEGFR‐3. VEGF‐C expression was observed frequently in patients with adenocarcinoma (P = 0.026). For VEGFR‐3 expression, significant correlations were demonstrated with age (P = 0.02), gender (P = 0.008), and histologic differentiation in patients with squamous cell carcinoma (P = 0.03). Patients who had positive staining for VEGF‐C showed significantly less favorable survival rates compared with patients who had negative staining for VEGF‐C (P = 0.003). The survival rates of patients who had positive staining for VEGFR‐3 also were significantly lower compared with patients who had negative staining for VEGFR‐3 (P < 0.001). Patients who had positive staining for both VEGF‐C and VEGFR‐3 exhibited the most unfavorable prognoses. Univariate analysis revealed the following prognostic factors: gender (P = 0.03), tumor status (T1,T2 vs. T3; P < 0.01), lymph node status (negative vs. positive; P < 0.01), tumor size (≤ 35 mm vs. > 35 mm; P < 0.01), disease stage (Stage I vs. Stages II and III; P < 0.01), VEGF‐C expression (negative vs. positive; P < 0.01), VEGFR‐3 expression (negative vs. positive; P < 0.01) and combined VEGF‐C and/or VEGFR‐3 expression (both positive vs. VEGF‐C or VEGFR‐3 positive; P < 0.01). Multivariate analysis demonstrated that VEGFR‐3 expression was the only independent negative prognostic factor (P < 0.01).
CONCLUSIONS
VEGF‐C and VEGFR‐3 expression may be indicative of survival rates for patients with NSCLC. Cancer 2003;97:457–64. © 2003 American Cancer Society.
DOI 10.1002/cncr.11073
Patients who showed positive staining fo |
| doi_str_mv | 10.1002/cncr.11073 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cncr_11073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR11073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3243-e79ba3b1ff14e74ddc6a9e63c4b05934ebeae0d8e1302c070c9daeda4725a7ae3</originalsourceid><addsrcrecordid>eNqN0M9LwzAUwPEgipvTi3-A5OJF6EyadFmPUvwFQ0EUvJXX9HWLZOlIOsf-GP9XMzvwJl6SF_iQB19Czjkbc8bSa-20H3POlDggQ85ylTAu00MyZIxNk0yK9wE5CeEjPlWaiWMy4GnGp0KxIfkqrHFGg6XBzJ1p4ug00rahnxD02oKn6Oq2W6A1Ec19u-kWtAHdtZ4WFFz9H-hR42o3CGocXUFn0HWBbkwkrnVhCdZSjfGwazenGrw2rl3CKTlqwAY8298j8nZ3-1o8JLPn-8fiZpZokUqRoMorEBVvGi5RybrWE8hxIrSsWJYLiRUCsnqKXLBUM8V0XgPWIGMOUIBiRK76f7VvQ_DYlCtvluC3JWflrnG5a1z-NI74oserdbXE-pfuo0ZwuQexDNjGx6Qm_DqZ8TSfqOh47zbG4vaPlWXxVLz0y78BsZGYvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Arinaga, Mitsuyuki ; Noguchi, Tsuyoshi ; Takeno, Shinsuke ; Chujo, Masao ; Miura, Takashi ; Uchida, Yuzo</creator><creatorcontrib>Arinaga, Mitsuyuki ; Noguchi, Tsuyoshi ; Takeno, Shinsuke ; Chujo, Masao ; Miura, Takashi ; Uchida, Yuzo</creatorcontrib><description><![CDATA[BACKGROUND
Vascular endothelial growth factor C (VEGF‐C) plays an important role in lymphangiogenesis and activates VEGF receptor 3 (VEGFR‐3). By contrast, lymphatic spread is an important prognostic factor in patients with nonsmall cell lung carcinoma (NSCLC). The objective of the current study was to determine whether the expression of VEGF‐C and VEGFR‐3 correlates with clinicopathologic factors and prognosis in patients with primary NSCLC.
METHODS
The authors conducted a retrospective review of 180 consecutive patients who underwent complete resection for NSCLC and who did not receive any chemotherapy or radiotherapy prior to surgery. Immunohistochemical staining for VEGF‐C and VEGFR‐3 was performed. The clinicopathologic implications of VEGF‐C and VEGFR‐3 expression were analyzed statistically.
RESULTS
Of 180 patients with NSCLC, 137 patients (76.1%) were positive for VEGF‐C, and 40 patients (22.2%) were positive for VEGFR‐3. VEGF‐C expression was observed frequently in patients with adenocarcinoma (P = 0.026). For VEGFR‐3 expression, significant correlations were demonstrated with age (P = 0.02), gender (P = 0.008), and histologic differentiation in patients with squamous cell carcinoma (P = 0.03). Patients who had positive staining for VEGF‐C showed significantly less favorable survival rates compared with patients who had negative staining for VEGF‐C (P = 0.003). The survival rates of patients who had positive staining for VEGFR‐3 also were significantly lower compared with patients who had negative staining for VEGFR‐3 (P < 0.001). Patients who had positive staining for both VEGF‐C and VEGFR‐3 exhibited the most unfavorable prognoses. Univariate analysis revealed the following prognostic factors: gender (P = 0.03), tumor status (T1,T2 vs. T3; P < 0.01), lymph node status (negative vs. positive; P < 0.01), tumor size (≤ 35 mm vs. > 35 mm; P < 0.01), disease stage (Stage I vs. Stages II and III; P < 0.01), VEGF‐C expression (negative vs. positive; P < 0.01), VEGFR‐3 expression (negative vs. positive; P < 0.01) and combined VEGF‐C and/or VEGFR‐3 expression (both positive vs. VEGF‐C or VEGFR‐3 positive; P < 0.01). Multivariate analysis demonstrated that VEGFR‐3 expression was the only independent negative prognostic factor (P < 0.01).
CONCLUSIONS
VEGF‐C and VEGFR‐3 expression may be indicative of survival rates for patients with NSCLC. Cancer 2003;97:457–64. © 2003 American Cancer Society.
DOI 10.1002/cncr.11073
Patients who showed positive staining for vascular endothelial growth factor C showed significantly unfavorable survival compared with patients who showed negative staining. Vascular endothelial growth factor receptor 3 expression was an independent negative prognostic factor for nonsmall cell lung carcinoma.]]></description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.11073</identifier><identifier>PMID: 12518370</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Endothelial Growth Factors - metabolism ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; nonsmall cell lung carcinoma ; Pneumology ; Prognosis ; Retrospective Studies ; Survival Analysis ; Tumors of the respiratory system and mediastinum ; Vascular Endothelial Growth Factor C ; vascular endothelial growth factor receptor 3 ; Vascular Endothelial Growth Factor Receptor-3 - metabolism</subject><ispartof>Cancer, 2003-01, Vol.97 (2), p.457-464</ispartof><rights>Copyright © 2003 American Cancer Society</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 American Cancer Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3243-e79ba3b1ff14e74ddc6a9e63c4b05934ebeae0d8e1302c070c9daeda4725a7ae3</citedby><cites>FETCH-LOGICAL-c3243-e79ba3b1ff14e74ddc6a9e63c4b05934ebeae0d8e1302c070c9daeda4725a7ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.11073$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.11073$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14512967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12518370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arinaga, Mitsuyuki</creatorcontrib><creatorcontrib>Noguchi, Tsuyoshi</creatorcontrib><creatorcontrib>Takeno, Shinsuke</creatorcontrib><creatorcontrib>Chujo, Masao</creatorcontrib><creatorcontrib>Miura, Takashi</creatorcontrib><creatorcontrib>Uchida, Yuzo</creatorcontrib><title>Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description><![CDATA[BACKGROUND
Vascular endothelial growth factor C (VEGF‐C) plays an important role in lymphangiogenesis and activates VEGF receptor 3 (VEGFR‐3). By contrast, lymphatic spread is an important prognostic factor in patients with nonsmall cell lung carcinoma (NSCLC). The objective of the current study was to determine whether the expression of VEGF‐C and VEGFR‐3 correlates with clinicopathologic factors and prognosis in patients with primary NSCLC.
METHODS
The authors conducted a retrospective review of 180 consecutive patients who underwent complete resection for NSCLC and who did not receive any chemotherapy or radiotherapy prior to surgery. Immunohistochemical staining for VEGF‐C and VEGFR‐3 was performed. The clinicopathologic implications of VEGF‐C and VEGFR‐3 expression were analyzed statistically.
RESULTS
Of 180 patients with NSCLC, 137 patients (76.1%) were positive for VEGF‐C, and 40 patients (22.2%) were positive for VEGFR‐3. VEGF‐C expression was observed frequently in patients with adenocarcinoma (P = 0.026). For VEGFR‐3 expression, significant correlations were demonstrated with age (P = 0.02), gender (P = 0.008), and histologic differentiation in patients with squamous cell carcinoma (P = 0.03). Patients who had positive staining for VEGF‐C showed significantly less favorable survival rates compared with patients who had negative staining for VEGF‐C (P = 0.003). The survival rates of patients who had positive staining for VEGFR‐3 also were significantly lower compared with patients who had negative staining for VEGFR‐3 (P < 0.001). Patients who had positive staining for both VEGF‐C and VEGFR‐3 exhibited the most unfavorable prognoses. Univariate analysis revealed the following prognostic factors: gender (P = 0.03), tumor status (T1,T2 vs. T3; P < 0.01), lymph node status (negative vs. positive; P < 0.01), tumor size (≤ 35 mm vs. > 35 mm; P < 0.01), disease stage (Stage I vs. Stages II and III; P < 0.01), VEGF‐C expression (negative vs. positive; P < 0.01), VEGFR‐3 expression (negative vs. positive; P < 0.01) and combined VEGF‐C and/or VEGFR‐3 expression (both positive vs. VEGF‐C or VEGFR‐3 positive; P < 0.01). Multivariate analysis demonstrated that VEGFR‐3 expression was the only independent negative prognostic factor (P < 0.01).
CONCLUSIONS
VEGF‐C and VEGFR‐3 expression may be indicative of survival rates for patients with NSCLC. Cancer 2003;97:457–64. © 2003 American Cancer Society.
DOI 10.1002/cncr.11073
Patients who showed positive staining for vascular endothelial growth factor C showed significantly unfavorable survival compared with patients who showed negative staining. Vascular endothelial growth factor receptor 3 expression was an independent negative prognostic factor for nonsmall cell lung carcinoma.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Endothelial Growth Factors - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>nonsmall cell lung carcinoma</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vascular Endothelial Growth Factor C</subject><subject>vascular endothelial growth factor receptor 3</subject><subject>Vascular Endothelial Growth Factor Receptor-3 - metabolism</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0M9LwzAUwPEgipvTi3-A5OJF6EyadFmPUvwFQ0EUvJXX9HWLZOlIOsf-GP9XMzvwJl6SF_iQB19Czjkbc8bSa-20H3POlDggQ85ylTAu00MyZIxNk0yK9wE5CeEjPlWaiWMy4GnGp0KxIfkqrHFGg6XBzJ1p4ug00rahnxD02oKn6Oq2W6A1Ec19u-kWtAHdtZ4WFFz9H-hR42o3CGocXUFn0HWBbkwkrnVhCdZSjfGwazenGrw2rl3CKTlqwAY8298j8nZ3-1o8JLPn-8fiZpZokUqRoMorEBVvGi5RybrWE8hxIrSsWJYLiRUCsnqKXLBUM8V0XgPWIGMOUIBiRK76f7VvQ_DYlCtvluC3JWflrnG5a1z-NI74oserdbXE-pfuo0ZwuQexDNjGx6Qm_DqZ8TSfqOh47zbG4vaPlWXxVLz0y78BsZGYvQ</recordid><startdate>20030115</startdate><enddate>20030115</enddate><creator>Arinaga, Mitsuyuki</creator><creator>Noguchi, Tsuyoshi</creator><creator>Takeno, Shinsuke</creator><creator>Chujo, Masao</creator><creator>Miura, Takashi</creator><creator>Uchida, Yuzo</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030115</creationdate><title>Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma</title><author>Arinaga, Mitsuyuki ; Noguchi, Tsuyoshi ; Takeno, Shinsuke ; Chujo, Masao ; Miura, Takashi ; Uchida, Yuzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3243-e79ba3b1ff14e74ddc6a9e63c4b05934ebeae0d8e1302c070c9daeda4725a7ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Endothelial Growth Factors - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>nonsmall cell lung carcinoma</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vascular Endothelial Growth Factor C</topic><topic>vascular endothelial growth factor receptor 3</topic><topic>Vascular Endothelial Growth Factor Receptor-3 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arinaga, Mitsuyuki</creatorcontrib><creatorcontrib>Noguchi, Tsuyoshi</creatorcontrib><creatorcontrib>Takeno, Shinsuke</creatorcontrib><creatorcontrib>Chujo, Masao</creatorcontrib><creatorcontrib>Miura, Takashi</creatorcontrib><creatorcontrib>Uchida, Yuzo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arinaga, Mitsuyuki</au><au>Noguchi, Tsuyoshi</au><au>Takeno, Shinsuke</au><au>Chujo, Masao</au><au>Miura, Takashi</au><au>Uchida, Yuzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2003-01-15</date><risdate>2003</risdate><volume>97</volume><issue>2</issue><spage>457</spage><epage>464</epage><pages>457-464</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract><![CDATA[BACKGROUND
Vascular endothelial growth factor C (VEGF‐C) plays an important role in lymphangiogenesis and activates VEGF receptor 3 (VEGFR‐3). By contrast, lymphatic spread is an important prognostic factor in patients with nonsmall cell lung carcinoma (NSCLC). The objective of the current study was to determine whether the expression of VEGF‐C and VEGFR‐3 correlates with clinicopathologic factors and prognosis in patients with primary NSCLC.
METHODS
The authors conducted a retrospective review of 180 consecutive patients who underwent complete resection for NSCLC and who did not receive any chemotherapy or radiotherapy prior to surgery. Immunohistochemical staining for VEGF‐C and VEGFR‐3 was performed. The clinicopathologic implications of VEGF‐C and VEGFR‐3 expression were analyzed statistically.
RESULTS
Of 180 patients with NSCLC, 137 patients (76.1%) were positive for VEGF‐C, and 40 patients (22.2%) were positive for VEGFR‐3. VEGF‐C expression was observed frequently in patients with adenocarcinoma (P = 0.026). For VEGFR‐3 expression, significant correlations were demonstrated with age (P = 0.02), gender (P = 0.008), and histologic differentiation in patients with squamous cell carcinoma (P = 0.03). Patients who had positive staining for VEGF‐C showed significantly less favorable survival rates compared with patients who had negative staining for VEGF‐C (P = 0.003). The survival rates of patients who had positive staining for VEGFR‐3 also were significantly lower compared with patients who had negative staining for VEGFR‐3 (P < 0.001). Patients who had positive staining for both VEGF‐C and VEGFR‐3 exhibited the most unfavorable prognoses. Univariate analysis revealed the following prognostic factors: gender (P = 0.03), tumor status (T1,T2 vs. T3; P < 0.01), lymph node status (negative vs. positive; P < 0.01), tumor size (≤ 35 mm vs. > 35 mm; P < 0.01), disease stage (Stage I vs. Stages II and III; P < 0.01), VEGF‐C expression (negative vs. positive; P < 0.01), VEGFR‐3 expression (negative vs. positive; P < 0.01) and combined VEGF‐C and/or VEGFR‐3 expression (both positive vs. VEGF‐C or VEGFR‐3 positive; P < 0.01). Multivariate analysis demonstrated that VEGFR‐3 expression was the only independent negative prognostic factor (P < 0.01).
CONCLUSIONS
VEGF‐C and VEGFR‐3 expression may be indicative of survival rates for patients with NSCLC. Cancer 2003;97:457–64. © 2003 American Cancer Society.
DOI 10.1002/cncr.11073
Patients who showed positive staining for vascular endothelial growth factor C showed significantly unfavorable survival compared with patients who showed negative staining. Vascular endothelial growth factor receptor 3 expression was an independent negative prognostic factor for nonsmall cell lung carcinoma.]]></abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12518370</pmid><doi>10.1002/cncr.11073</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2003-01, Vol.97 (2), p.457-464 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_cncr_11073 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Endothelial Growth Factors - metabolism Female Humans Immunohistochemistry Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - surgery Male Medical sciences Middle Aged Multivariate Analysis nonsmall cell lung carcinoma Pneumology Prognosis Retrospective Studies Survival Analysis Tumors of the respiratory system and mediastinum Vascular Endothelial Growth Factor C vascular endothelial growth factor receptor 3 Vascular Endothelial Growth Factor Receptor-3 - metabolism |
| title | Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A27%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20vascular%20endothelial%20growth%20factor%20C%20and%20vascular%20endothelial%20growth%20factor%20receptor%203%20in%20patients%20with%20nonsmall%20cell%20lung%20carcinoma&rft.jtitle=Cancer&rft.au=Arinaga,%20Mitsuyuki&rft.date=2003-01-15&rft.volume=97&rft.issue=2&rft.spage=457&rft.epage=464&rft.pages=457-464&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.11073&rft_dat=%3Cwiley_cross%3ECNCR11073%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12518370&rfr_iscdi=true |